5 Common CBD Myths, and What the Evidence Actually Says

Myth 1: 'CBD is a cure-all.' — No single compound addresses the breadth of conditions sometimes claimed in CBD marketing. The strongest evidence remains narrowly concentrated (notably, specific seizure disorders), while many other claimed benefits remain in preliminary or emerging research stages at best.

Myth 2: 'More milligrams always means a stronger effect.' — Individual response to CBD varies based on body chemistry, the condition or goal in question, delivery method, and bioavailability — dosage isn't a simple linear dial, and 'start low and go slow' remains common general guidance for anyone trying a new product.

Myth 3: 'CBD can't show up on a drug test.' — Most drug tests screen for THC metabolites, not CBD itself. However, full-spectrum products containing trace THC can, in some cases, accumulate to detectable levels with regular use, depending on individual metabolism and testing sensitivity. People with drug testing concerns often choose broad-spectrum or isolate products specifically to reduce (not necessarily eliminate) this risk.

Myth 4: 'All hemp-derived CBD is federally legal everywhere.' — Hemp-derived CBD with under 0.3% THC is federally legal in the U.S., but individual states retain authority to further restrict or regulate it, and other countries have entirely different legal frameworks. 'Federally legal' and 'legal everywhere' are not the same thing.

Myth 5: 'Natural means risk-free.' — CBD can interact with certain medications (notably those metabolized via the liver's CYP450 enzyme pathway, similar to grapefruit's known drug interactions) and isn't automatically risk-free simply because it's plant-derived. Anyone taking prescription medication should discuss CBD use with a healthcare provider first.